Contributor Page
Email  |  Website  |  Articles
Contact Details
Tel: +44 20 7632 7200
Fax: +44 20 7353 8895
St Bride's House
10 Salisbury Square
By Christopher Wilkins
Attitudes towards the use of cannabis, both recreationally and therapeutically, have shifted significantly in recent years. Recreational cannabis was legalised in Canada
By Michelle Menné
Take a look at our recent recruitment video for some insight into day-to-day life at our Dehns offices.
By Adam Kellett
Kim Kardashian will no doubt be pleased to have been awarded $2.7 million in damages, in a court case against the fashion brand Missguided.
By Emma Tyser
Over 5 years ago, Adidas successfully registered its three stripes as a trade mark in the EU in relation to clothing, footwear and headgear.
By Oliver Gray
As reported in our article of 30 November 2018, changes to the Canadian Trade-marks Act 1985 will shortly enter into force on 17 June 2019.
By Mark Bell
In a surprise development, Apple and Qualcomm have settled their billion dollar smartphone litigation cases worldwide.
By Dehns  
There is still considerable uncertainty around Brexit: when will the UK leave the EU? Will there be an agreed deal? What will the deal look like? What happens if no deal is agreed?
By Mark Scott
Over the last few years, the EPO Boards of Appeal have become more strict regarding the late filing of new facts, evidence or requests.
By Daniel Rowe
The EPO's practice on double patenting has been rather settled over the past decade. As indicated in the EPO's Guidelines for Examination ...
By Adam Kellett
The Kardashian/Jenner family have made millions by commodifying their personal lives and turning themselves into powerhouse brands.
By Adam Kellett
The term intellectual property (IP) refers to a variety of different types of legal rights.
By Mark Bell
Once again, the German Federal Constitutional Court has listed the "Constitutional Complaint" against German ratification of the Unified Patent Court Agreement on the cases to be decided for the coming year.
By Chris Goddard
It was great to share pharmaceutical patenting insights with the panel and our audience at the "Patent Challenges in the Pharma Industry"
By Chris Goddard
IP practice around Europe is at its most inconsistent when it comes to Supplementary Protection Certificate (SPC) protection for second and further medical indication inventions.
By Tom Lorkin
In what may come as a welcome departure from existing practice, an EPO board of appeal in decision T1085/13 has clarified the conditions under which patents can be granted for known compounds